Roundtable: The Next Buyouthttp://www.fool.com/investing/general/2010/06/29/roundtable-the-next-buyout.aspx Andy Cross
June 29, 2010
The buyout-rumor knitting circle was giddy last week. Word leaked that Motley Fool Stock Advisor core stock Hasbro (NYSE: HAS ) was entertaining a buyout offer from a private equity firm. Shares soon shot up on the prospect of a healthy premium.
The toy giant ultimately squashed the rumors, but it got me and my fellow Stock Advisor analysts thinking about which company could be the next buyout target for the billions of dollars of private equity cash sitting on the sidelines.
Here are some ideas.
Matthew Argersinger, analyst
Whether it's story-based games such as Mafia, strategy games such as Civilization, or first-person-shooters such as Bioshock, Take-Two Interactive's (Nasdaq: TTWO ) rich portfolio of intellectual property is the envy of the video game industry. And let's not forget about Grand Theft Auto, which virtually guarantees $1 billion to Take-Two's coffers every time a sequel is released.
Yet Take-Two has suffered from a history of managerial missteps and inconsistent profitability. It is no surprise then that it's been the subject of buyout attempts in the past, including a fairly rancorous attempt by rival Electronic Arts back in 2008. That deal fell through, but private equity titan Carl Icahn recently bought a 10% stake and muscled his way onto Take-Two's board.
Only time will tell if Icahn's domineering presence results in a take-private deal. But with such valuable assets and a severely beaten-down stock price -- buyout or not -- I think Take-Two is a market-beater from here.
Andy Cross, associate advisor
One stock I've been watching is Neogen (Nasdaq: NEOG ) , a maker of food safety testing kits and veterinarian products. This small-cap company rings up plenty of cash that it uses to make small acquisitions to grow its niche businesses. During the past five years, it grew its revenues 16% per year and operating earnings by 24%. Its balance sheet is debt-free, and its founder and CEO owns more than 4% of the company. The stock has smoked the market so far this year and sells at an above market earnings multiple, but at the right price, Neogen looks worth a nibble.
Bryan White, analyst
While most health IT names have run up, Athenahealth (Nasdaq: ATHN ) has lost about half of its value over the past six months due to lawsuits surrounding accounting errors. Electronic health record adoption over the next three to five years should provide a large enough tailwind to raise most ships in this space, and Athenahealth looks the cheapest.
One of the problems with expanding health insurance to all